Physician

Ahmet Bahadir Ergin, M.D.

According to 2025 Medicare claims, Ahmet Ergin, M.D. (NPI: 1023247111) practices endocrinology in the Port St. Lucie, FL market, with the plurality of this provider's patient population coming from St. Lucie, FL. This provider's primary affiliated billing organization is DIABETES THYROID & HORMONE CENTER OF THE TREASURE COAST, PLLC (NPI: 1316785017; TIN: 993800266) and primary practice location at 34952-7536.

Ergin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 597 traditional Medicare patients, billed 2,831 HCPCS/CPT codes, and received $188,703 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 10,876 prescription claims across 1,239 beneficiaries totaling $6,325,060 in drug costs, led by Ozempic (Semaglutide). DME data shows 722 claims. Open Payments data shows 158 records totaling $24,487. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $1,458,664 to $6,325,060. For DME billing, reported payments rose steadily, from $23,764 to $276,156.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	585	3,581	$172,044
2016	835	2,826	$150,331
2017	801	3,592	$224,345
2018	544	2,611	$149,216
2019	405	3,023	$162,881
2020	481	2,288	$148,854
2021	545	2,715	$202,899
2022	552	2,391	$173,549
2023	601	2,507	$172,115
2024	597	2,831	$188,703

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	531	5,855	$1,458,664
2016	664	6,445	$1,835,574
2017	408	1,491	$557,830
2018	371	1,743	$984,093
2019	614	4,157	$3,197,085
2020	749	5,147	$3,886,654
2021	892	5,635	$3,870,544
2022	934	7,166	$5,029,042
2023	1,096	8,703	$6,495,009
2024	1,239	10,876	$6,325,060

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	159	342	$27,668
2016	347	884	$59,978
2017	58	165	$36,593
2018	116	349	$73,802
2019	142	400	$55,416
2020	172	617	$92,554
2021	233	1,034	$167,813
2022	201	1,126	$192,231
2023	196	1,211	$228,156
2024	219	722	$275,697

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	145	145	$134
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	513	1,359	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	88	115	$71
95251	Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report	140	338	$28
36415	Insertion of needle into vein for collection of blood sample	172	371	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	1,108	54,248	$1,695,824
Mounjaro	Tirzepatide	564	20,343	$727,174
Jardiance	Empagliflozin	533	32,949	$629,765
Kerendia	Finerenone	521	29,163	$620,476
Rybelsus	Semaglutide	125	7,840	$241,739

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	129	481	$232,758
E0784	External ambulatory infusion pump, insulin	Y	N/R	50	$16,572
A4238	Supply allowance for adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	21	$10,262
E2103	Non-adjunctive, non-implanted continuous glucose monitor or receiver	N	30	30	$6,596
A4224	Supplies for maintenance of insulin infusion catheter, per week	N	11	27	$6,092

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	158	$24,487	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ahmet Bahadir Ergin, M.D.?

Tedicare shows public-source Medicare data for Ahmet Bahadir Ergin, M.D. (NPI 1023247111), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ahmet Bahadir Ergin, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ahmet Bahadir Ergin, M.D.?

Ahmet Bahadir Ergin, M.D. is linked to DIABETES THYROID & HORMONE CENTER OF THE TREASURE COAST, PLLC (billing NPI 1316785017) in the available physician profile data.

Does Ahmet Bahadir Ergin, M.D. have Open Payments data?

Ahmet Bahadir Ergin, M.D. has 158 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.